• ,

Diabetic Nephropathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

Diabetic Nephropathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Diabetic Nephropathy Pipeline Insights
“Diabetic Nephropathy Pipeline Insights, 2023” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Nephropathy market. A detailed picture of the Diabetic Nephropathy pipeline landscape is provided, which includes the disease overview and Diabetic Nephropathy treatment guidelines.

United States, Nevada, Las Vegas, DelveInsight’s Diabetic Nephropathy Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Nephropathy pipeline domain.

Key Takeaways from the Diabetic Nephropathy Pipeline Report

  • Over 34+ Diabetic Nephropathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Nephropathy market would significantly increase market revenue. 
  • Leading Diabetic Nephropathy companies developing novel drug candidates to improve the Diabetic Nephropathy treatment landscape include Bayer, Novartis, Boehringer Ingelheim, CSL Behring, and others.
  • Promising Diabetic Nephropathy pipeline therapies in various stages of development include Finerenone, Nidufexor (LMB763),  BI 685509, CSL346, and others.

Diabetic Nephropathy Overview

Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It is also known as Diabetic Kidney Disease (DKD). It happens when elevated blood glucose levels damage a person’s kidneys.

Diabetic nephropathy is a leading cause of chronic kidney disease and end-stage renal disease (ESRD). The kidneys in ESRD can no longer satisfy everyday life’s demands. Kidney failure can result from ESRD, which can be life-threatening.

Diabetic Nephropathy Pipeline Analysis: Drug Profile

AUP 16: Aurealis Therapeutics

Finerenone (BAY94-8862), a Nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer commenced a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III FIDELIO-DKD study in September 2015 to investigate the safety and efficacy of Finerenone  in addition to standard of care in subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease. This trial was completed in April 2020. During the start of 2021, the company announced about their  New Drug Application (NDA) and granted Priority Review. The findings from the Phase III FIDELIO-DKD study, which were presented in detail at the American Society of Nephrology’s (ASN) Kidney Week Reimagined 2020 and subsequently published in the New England Journal of Medicine in October 2020, were used to support this regulatory filing.

Discover more about the emerging Diabetic Nephropathy drugs @ Diabetic Nephropathy Treatment Drugs

Diabetic Nephropathy Key Companies

  • Bayer
  • Novartis
  • Boehringer Ingelheim
  • CSL Behring

Diabetic Nephropathy Pipeline Therapies

  • Finerenone
  • Nidufexor (LMB763)
  • BI 685509
  • CSL346

Diabetic Nephropathy Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diabetic Nephropathy Pipeline Report 

  • Coverage: Global 
  • Key Diabetic Nephropathy Companies: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others
  • Key Diabetic Nephropathy Pipeline Therapies: Finerenone, Nidufexor (LMB763),  BI 685509, CSL346, and others

Find out more about the Diabetic Nephropathy treatment options in development @ Diabetic Nephropathy Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Diabetic Nephropathy pipeline segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/